Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

194.75 -1.28 (-0.65%)

Streaming Delayed Price Updated: 2:46 PM EDT, Sep 25, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	564,602
Open	197.68
Bid (Size)	194.53 (200)
Ask (Size)	194.97 (300)
Prev. Close	196.03
Today's Range	194.54 - 201.42
52wk Range	115.31 - 260.19
Shares Outstanding	47,190,970
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day

September 21, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Sees AUVELITY Prescriptions Accelerate as Alzheimer’s Launch Gains Traction ↗

September 19, 2026

Axsome Therapeutics (NASDAQ:AXSM) executives said the company is seeing accelerating prescription growth for AUVELITY following its sales-force expansion and the recent launch of the drug in...

Via MarketBeat

Performance

YTD	+9.0%	+9.0%
1 Month	-5.2%	-5.2%
3 Month	-17.9%	-17.9%
6 Month	+18.6%	+18.6%
1 Year	+64.0%	+64.0%

More News

Axsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference ↗

September 19, 2026

Via MarketBeat

Analysts Think Axsome Therapeutics Stock Could Soar 35% Over the Next 12 Months. Is the Stock a No-Brainer Buy? ↗

September 18, 2026

Via The Motley Fool

Axsome Therapeutics vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 18, 2026

Via The Motley Fool

Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 18, 2026

Via The Motley Fool

Is Axsome Therapeutics a Buy on the Dip? ↗

September 18, 2026

Via The Motley Fool

Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026

September 17, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 11, 2026

Via The Motley Fool

Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 10, 2026

Via The Motley Fool

Axsome Therapeutics to Participate in Upcoming Investor Conferences

September 02, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation

August 31, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗

August 29, 2026

Via The Motley Fool

Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to Run ↗

August 23, 2026

Via The Motley Fool

Here’s How Much You Would Have Made Owning Axsome Therapeutics Stock In The Last 5 Years ↗

August 17, 2026

Via Benzinga

If You Invested $100 In Axsome Therapeutics Stock 10 Years Ago, You Would Have This Much Today ↗

August 13, 2026

Via Benzinga

Axsome Therapeutics Analysts Increase Their Forecasts Following Q2 Results ↗

August 11, 2026

Via Benzinga

Axsome Therapeutics Q2 Earnings Call Highlights ↗

August 10, 2026

Via MarketBeat

Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 10, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Prediction: These 2 Stocks Will Keep Winning No Matter What the Market Does ↗

August 04, 2026

Via The Motley Fool

Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy

July 15, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10

July 14, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

3 Under-the-Radar Stocks to Buy and Hold ↗

July 10, 2026

Via The Motley Fool

Better Growth Buy: Axsome vs Revolution Medicines ↗

July 09, 2026

Via The Motley Fool

Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)

July 07, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Axsome Therapeutics, Inc. - Common Stock publicly traded?

Yes, Axsome Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Axsome Therapeutics, Inc. - Common Stock trade on?

Axsome Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Axsome Therapeutics, Inc. - Common Stock?

The ticker symbol for Axsome Therapeutics, Inc. - Common Stock is AXSM on the Nasdaq Stock Market

What is the current price of Axsome Therapeutics, Inc. - Common Stock?

The current price of Axsome Therapeutics, Inc. - Common Stock is 194.75

When was Axsome Therapeutics, Inc. - Common Stock last traded?

The last trade of Axsome Therapeutics, Inc. - Common Stock was at 09/25/26 02:46 PM ET

What is the market capitalization of Axsome Therapeutics, Inc. - Common Stock?

The market capitalization of Axsome Therapeutics, Inc. - Common Stock is 9.19B

How many shares of Axsome Therapeutics, Inc. - Common Stock are outstanding?

Axsome Therapeutics, Inc. - Common Stock has 9B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.